Literature DB >> 27593932

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.

A B Lee-Sherick, K M Eisenman, S Sather, A McGranahan, P M Armistead, C S McGary, S A Hunsucker, J Schlegel, H Martinson, C Cannon, A K Keating, H S Earp, X Liang, D DeRyckere, D K Graham.   

Abstract

Entities:  

Year:  2016        PMID: 27593932      PMCID: PMC5143365          DOI: 10.1038/onc.2016.295

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


× No keyword cloud information.
Correction to: Oncogene (2013) 32, 5359-5368; doi:10.1038/onc.2013.40; published online 11 March 2013 Since the publication of this article, the authors have identified two inadvertent errors in Figure 3.
Figure 3

Merstimulation in AML cells activates oncogenic signaling pathways. Kasumi-1 and NOMO-1 cells were incubated in serum-free RPMI medium for two to three hours and then treated with 200nM rhGas6 or buffer. (c) Diluted lysates were incubated with human phospho-kinase array membranes and bound phospho-proteins were detected according to kit instructions. Each membrane contains positive control (P) antibodies spotted in duplicate. Proteins that demonstrated a 1.5-fold or greater increase in phosphorylation after stimulation with Gas6 (Gas6 treated) relative to buffer treated samples (Untreated) are marked by numbers between duplicate spots, which correlate with the identification numbers shown in (d). (e) Cell lysates were prepared from cultures treated with rhGas6 (+) or buffer (−) and subjected to immunoblot analysis with antibodies specific for phosphorylated and total MSK1, p38, ERK1/2, STAT6, AKT, ATF1, and CREB proteins. Representative Kasumi-1 immunoblots are shown.

Merstimulation in AML cells activates oncogenic signaling pathways. Kasumi-1 and NOMO-1 cells were incubated in serum-free RPMI medium for two to three hours and then treated with 200nM rhGas6 or buffer. (c) Diluted lysates were incubated with human phospho-kinase array membranes and bound phospho-proteins were detected according to kit instructions. Each membrane contains positive control (P) antibodies spotted in duplicate. Proteins that demonstrated a 1.5-fold or greater increase in phosphorylation after stimulation with Gas6 (Gas6 treated) relative to buffer treated samples (Untreated) are marked by numbers between duplicate spots, which correlate with the identification numbers shown in (d). (e) Cell lysates were prepared from cultures treated with rhGas6 (+) or buffer (−) and subjected to immunoblot analysis with antibodies specific for phosphorylated and total MSK1, p38, ERK1/2, STAT6, AKT, ATF1, and CREB proteins. Representative Kasumi-1 immunoblots are shown. First, the phosphoarray in Figure 3c listed as Kasumi-1 was a duplicate of the NOMO-1 cell line phosphoarray. The Kasumi-1 and NOMO-1 data were correctly analyzed and represented graphically in Figure 3d. A revised version of Figure 3c with images of both the Kasumi-1 and NOMO-1 phosphoarrays is shown. In addition, it came to our attention that some panels in Figure 3e were mislabeled and one set of loading controls were shown in duplicate. In the revised version derived from the Kasumi-1 cell line, correct phospho- and total protein immunoblots and corresponding loading controls are shown. The revised data support the conclusions originally reported in this manuscript and the text of the manuscript remains unchanged. The authors apologize for any inconvenience this may have caused.
  7 in total

1.  Irf8 regulates the progression of myeloproliferative neoplasm-like syndrome via Mertk signaling in zebrafish.

Authors:  F Zhao; Y Shi; Y Huang; Y Zhan; L Zhou; Y Li; Y Wan; H Li; H Huang; H Ruan; L Luo; L Li
Journal:  Leukemia       Date:  2017-06-19       Impact factor: 11.528

2.  The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.

Authors:  B R Branchford; T J Stalker; L Law; G Acevedo; S Sather; C Brzezinski; K M Wilson; K Minson; A B Lee-Sherick; P Davizon-Castillo; C Ng; W Zhang; K B Neeves; S R Lentz; X Wang; S V Frye; H Shelton Earp; D DeRyckere; L F Brass; D K Graham; J A Di Paola
Journal:  J Thromb Haemost       Date:  2018-01-12       Impact factor: 5.824

Review 3.  Molecular insights of Gas6/TAM in cancer development and therapy.

Authors:  Guiling Wu; Zhiqiang Ma; Wei Hu; Dongjin Wang; Bing Gong; Chongxi Fan; Shuai Jiang; Tian Li; Jianyuan Gao; Yang Yang
Journal:  Cell Death Dis       Date:  2017-03-23       Impact factor: 8.469

Review 4.  Efferocytosis and Its Associated Cytokines: A Light on Non-tumor and Tumor Diseases?

Authors:  Danfeng Lin; Xiaodiao Kang; Lu Shen; Sheng Tu; Cameron Lenahan; Yiding Chen; Xiaochen Wang; Anwen Shao
Journal:  Mol Ther Oncolytics       Date:  2020-04-28       Impact factor: 7.200

Review 5.  Immuno-oncology: are TAM receptors in glioblastoma friends or foes?

Authors:  Yunxiang Zhou; Yali Wang; Hailong Chen; Yanyan Xu; Yi Luo; Yongchuan Deng; Jianmin Zhang; Anwen Shao
Journal:  Cell Commun Signal       Date:  2021-01-28       Impact factor: 5.712

Review 6.  Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.

Authors:  Dan Yan; H Shelton Earp; Deborah DeRyckere; Douglas K Graham
Journal:  Cancers (Basel)       Date:  2021-11-11       Impact factor: 6.639

Review 7.  Targeting Gas6/TAM in cancer cells and tumor microenvironment.

Authors:  Guiling Wu; Zhiqiang Ma; Yicheng Cheng; Wei Hu; Chao Deng; Shuai Jiang; Tian Li; Fulin Chen; Yang Yang
Journal:  Mol Cancer       Date:  2018-01-31       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.